Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Remibrutinib in Chronic Spontaneous Urticaria Extension Study
NCT04109313Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of remibrutinib in chronic spontaneous urticaria (CSU), sponsored by Novartis. Primary endpoint: Number of Participants With Treatment-emergent Adverse Events at 56 weeks. Started Oct 2019; status: completed.
02
Drugs
remibrutinib
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT04109313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04109313.